

08-15-02

GP1614
Box 1600/2900
RECEIVEDPlease type a plus sign inside this box → ☐

Approved for use through 10/31/2002. OMB 065-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/716,778	
	Filing Date	November 20, 2000	
	First Named Inventor	Mühlradt et al.	
	Group Art Unit	1614	
	Examiner Name	to be assigned	
Total Number of Pages in This Submission	46	Attorney Docket Number	29473/11899

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below)
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Submission of Substitute Translation (20 pgs.), Substitute Amended Specification (20 pgs.), and Sequence listing (4 pgs. plus disk)
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

RECEIVED


MAR 19 2003

TECH CENTER 1600/2900

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual Name	MARSHALL, GERSTEIN & BORUN Nabeela R. McMillian - 43,363
Signature	
Date	August 14, 2002

DATE:



DISK TO STIC

RECEIVED


AUG 20 2002

OFFICE OF PETITIONS

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, EV180483568US, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: August 14, 2002

Signature: (Richard Zimmermann)



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as Express Mail, EV180483568US, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: August 14, 2002

Signature: 
Richard Zimmermann

RECEIVED
AUG 19 2002
TECH CENTER 1600/2900
Docket No.: 2947/11899
(PAY-2900)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Mühlradt et al.

Application No.: 09/716,778

Group Art Unit: 1614

Filed: November 20, 2000

Examiner: To be Assigned

For: Use of Lipopeptides or Lipoproteins for
Wound Treatment

RECEIVED
MAR 19 2003

TECH CENTER 1600/2900

SUBMISSION OF SUBSTITUTE TRANSLATION, SUBSTITUTE AMENDED
SPECIFICATION AND SEQUENCE LISTING

Commissioner for Patents
Washington, D.C. 20231

RECEIVED
AUG 20 2002

OFFICE OF PETITIONS

Dear Sir:

On October 11, 2001, Applicants petitioned for suspension of action in the above-captioned application, pursuant to 37 C.F.R. §1.103, in order to allow Applicants to provide a substitute translation of the application. Submitted herewith is a substitute verified translation of the application (**Appendix A**). Applicants request examination of the above-referenced application be resumed.

Upon reviewing the translation, Applicants note that the format of the specification was such that it did not comport with the specification formalities required of United States Patent Applications. Namely, the specification did not contain the appropriate headings as suggested in MPEP §601 for "Summary of the invention", "Brief Description of the Drawings" and "Detailed Description of the Preferred Embodiments" and the "Abstract" was titled "Summary." The parent German language application made

addition, the present application contains amino acid sequences, in order to comply with 37 C.F.R. §1.821 the translated specification is required to make reference to the sequence identifiers (37 C.F.R. §1.821(d)). Thus, there were a number of amendments to the specification in order to make the specification conform to United States Patent Office practice, for the purposes of clarity, rather than presenting such amendments by way of a preliminary amendment, applicants provide herewith a **substitute specification (Appendix B)**. Applicants submit that the substitute specification does not contain new matter.

Also attached herewith are the sequence listing, diskette and statement regarding the sequence listing as required under 37 C.F.R. S§1.821-1.825.

Should the Examiner have any questions regarding this submission, Applicants invite the Examiner to contact the undersigned representative.

Dated: August 14, 2002

Respectfully submitted,

By 

Nabeela R. McMillian

Registration No.: 43,363

MARSHALL GERSTEIN & BORUN

Attorneys For Applicants

233 S. Wacker Drive,

Suite 6300 Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300